Bausch + Lomb Corporation
15.47+0.27 (+1.78%)
Oct 29, 4:00:02 PM EDT · NYSE · BLCO · USD
Key Stats
Market Cap
5.47BP/E (TTM)
-Basic EPS (TTM)
-0.78Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Icahn-linked directors resign
Bausch + Lomb's Director Appointment and Nomination Agreement with the Icahn Group terminated on August 14, 2025, after their net long position in parent Bausch Health Companies Inc. dropped below the threshold. Brett Icahn and Gary Hu resigned from the board that day, ending their three-year terms without disagreements. The company appreciates their contributions. Board shrinks by two.
8-K
Q2 revenue up 5%, guidance raised
Bausch + Lomb reported Q2 2025 revenue of $1.278 billion, up 5% from $1.216 billion last year, with Vision Care surging 8% to $753 million on strong contact lens and dry eye sales, while Surgical grew 3% to $216 million despite an enVista IOL recall. GAAP net loss narrowed to $62 million from $151 million, but Adjusted EBITDA dipped to $191 million. The company raised full-year guidance to $5.050B-$5.150B revenue and $860M-$910M Adjusted EBITDA excluding Acquired IPR&D. Refinancing extended debt maturities, yet recall risks linger.
10-Q
Q2 FY2025 results show revenue growth and improved profitability for Bausch + Lomb, with key metrics and outlook reaffirmed.
Bausch + Lomb Corporation's 10-Q filing for the quarter ended June 30, 2025, reports total revenues of $1.278 billion, up 5% year-over-year, driven by growth in vision care and surgical segments. Net loss attributable to Bausch + Lomb was $58 million, an improvement from $148 million in the prior year, with adjusted EBITDA of $269 million, reflecting a 14% margin. The company highlights strong performance in contact lenses and pharmaceuticals, offset by challenges in surgical equipment. Cash and equivalents stood at $266 million, with total debt at $5.024 billion. Bausch + Lomb maintains its full-year guidance for revenues between $4.95 billion and $5.05 billion and adjusted EBITDA between $1.05 billion and $1.10 billion. No material changes to risk factors or legal proceedings were noted.
IPO
Website
Employees
Sector
Industry
ALC
Alcon Inc.
73.60-1.22
BHC
Bausch Health Companies Inc.
5.90-0.29
COO
The Cooper Companies, Inc.
69.58-2.17
LNSR
LENSAR, Inc.
11.90+0.03
POCI
Precision Optics Corporation, I
4.26-0.01
RXST
RxSight, Inc.
8.43-0.38
SGHT
Sight Sciences, Inc.
5.04-0.13
STAA
STAAR Surgical Company
26.59-0.57
VYCO
Vycor Medical, Inc.
0.15+0.00
WRBY
Warby Parker Inc.
20.05-1.08